Sensei Biotherapeutics Inc (SNSE) - Total Liabilities
Based on the latest financial reports, Sensei Biotherapeutics Inc (SNSE) has total liabilities worth $14.19 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sensei Biotherapeutics Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Sensei Biotherapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See how liquid is Sensei Biotherapeutics Inc's working capital to evaluate short-term liquidity relative to the company's equity base.
Sensei Biotherapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Sensei Biotherapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GUH Holdings Bhd
KLSE:3247
|
Malaysia | RM220.56 Million |
|
Asset Vision Co Ltd
AU:ASV
|
Australia | AU$2.06 Million |
|
ASTORY Co.Ltd
KQ:241840
|
Korea | ₩10.09 Billion |
|
Predictive Oncology Inc
NASDAQ:POAI
|
USA | $80.57 Million |
|
Lottery.com Inc.
NASDAQ:SEGG
|
USA | $29.95 Million |
|
Prostar Holdings Inc
V:MAPS
|
Canada | CA$844.82K |
|
Asuransi Ramayana Tbk
JK:ASRM
|
Indonesia | Rp1.24 Trillion |
Liability Composition Analysis (2018–2025)
This chart breaks down Sensei Biotherapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Sensei Biotherapeutics Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sensei Biotherapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sensei Biotherapeutics Inc (2018–2025)
The table below shows the annual total liabilities of Sensei Biotherapeutics Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $4.31 Million | -38.21% |
| 2024-12-31 | $6.97 Million | -26.42% |
| 2023-12-31 | $9.48 Million | -36.67% |
| 2022-12-31 | $14.97 Million | +123.00% |
| 2021-12-31 | $6.71 Million | +21.26% |
| 2020-12-31 | $5.54 Million | -92.08% |
| 2019-12-31 | $69.88 Million | +26.29% |
| 2018-12-31 | $55.33 Million | -- |
About Sensei Biotherapeutics Inc
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune … Read more